Scott M. Lippman, MDDirector, Moores Cancer Center

April 14, 2014

2014 Cancer Center Administrators Forum

San Diego NCI Cancer Centers Council (C3):

A Model for Multi‐Institutional Transdisciplinary Collaboration

Evolution of the Moores Cancer Center

Moores Cancer Center Opened

Cancer Center FoundedJohn Mendelsohn, Director

CCSG Renewed

Scott Lippman Director

Awarded Comprehensive

Status

NCI-designated Cancer Center

UCSD SOMFounded

Napoleone FerraraBasic Science

Razelle KurzrockClinical Science

Ezra CohenTranslational

Science

CTSA Awarded

2

CCSG Renewal

‘14

Dennis Carson Director

S t r a t e g i c R e c r u i t s

UCSD Moores Cancer Center

Shared Resources

Nicholas Webster, PhD

Deputy DirectorBarbara Parker, MD

AdministrationIra Goodman, MPA, MS

Clinical Trials Office

External Advisory Board

Research Programs•Cancer Prevention•Reducing Cancer Disparities

Research Programs•Hematologic Malignancies•Solid Tumor Therapeutics

Division of Clinical Science

Razelle Kurzrock, MD

Division of Basic Science

Napoleone Ferrara, MD

Senior Advisor to the DirectorThomas Kipps, MD, PhD

Research Programs•Cancer Biology & Signaling•Cancer Genomics & Networks

Office of Industry Relations

Executive Committee

Cancer Cabinet

Board of Visitors

Division of Population Science

John Pierce, PhD

Center DirectorAssociate Vice Chancellor

for Cancer Research and CareScott Lippman, MD

Shared Resources (7)Biorepository & Tissue

TechnologyBiostatistics

Genomics & BioinformaticsMicroscopy

Flow CytometryTransgenic/KO Mice

Diet & Physical Activity

Shared Resources

Nicholas Webster, PhD

Division of Clinical Science

Razelle Kurzrock, MD

Division of Basic Science

Napoleone Ferrara, MD

Division of Population Science

John Pierce, PhD

3

Moores and Other Cancer Center Facilities on the UC San Diego Campus

MCC Moores Cancer Center

OP Outpatient Pavilion

CNT Center for Novel Therapeutics

Cancer CampusRelation to Consortium Partner SDSU

Altman CTRI CALM

JMCHCC

OP

MCC

CNT

FACILITIES

CALM Center for Advanced Laboratory Medicine

JMC Jacobs Medical Center- Hospital for Cancer Care

CTRI Clinical and Translational Research Institute

4

SCRM Sanford Consortium for Regenerative Medicine

LICR Ludwig Institute for Cancer Research

SIO Scripps Institution of Oceanography

LICR

SCRM

SIO

Catchment Area

121 miles

AZ Cancer Center410 miles

San Diego• 8th Largest city (1.33M)• 5th Largest county (3.14M)

Imperial County• Population = 175K• Poverty Rate = 23%

REGIONAL IMPACT

UC Irvine

UCLA

USC City of Hope

MCC

5

Clinical Hub of Unique Biomedical Environment

UCSD MOORES

THE SCRIPPS RESEARCH INSTITUTE

LA JOLLA ALLERGY AND IMMUNOLOGY

JCVI

2nd largest life-sciences cluster in US (Jones Lang LaSalle)

• Advisory & Innovation Council• Center for Novel Therapeutics (CNT)

LIFE TECHNOLOGIES

AMGEN

JANSSEN

NOVARTIS

ILLUMINA

PFIZER

MERCK

6

SDSU

16 milesJCVI

Sanford Consortium for Regenerative Medicine(opened Dec 2011; LIAI, Salk, S-B, MCC, TSRI)

SDSU San Diego State University(Formal consortium MOU signed Apr 2013)

(C3 MOU signed Oct 2012)

J. Craig Venter Institute - HLI(opened Nov 2013; HLI MOU signed Feb 2014)

SALK

SANFORD | BURNHAM

SCRM SALK

SANFORD | BURNHAM

C3 MOU signed(Oct 12, 2012)

MCC / C3 Formal Affiliations / Timeline

SDSU: Federally-designated Hispanic-serving Institute

(April 2012)

C3 Retreat(June 29,

2013)

Members from TSRI, LIAI & JCVI join MCC faculty

Sanford Consortium for Regenerative Medicine

(SCRM) opens (Dec 2011)

C3 Pilot Grant RFA(Feb 28, 2014)

Pedal the Cause Fundraiser

(Oct 26, 2013)

HLI MOU signed (Feb 2014)

SDSU: Formal consortium w/ MCC

MOU signed (Apr 2013)

Mahajani Symposium (Sep 9, 2013)

JCVI opened on UCSD Campus (Nov 2013)

C3 Reception at AACR

(Apr 7, 2014)

C3 Pilot Grant Awards

(May 1, 2014)

2012 2013 2014

Salk Gene Transfer Targeting S-B High Throughput ScreeningMCC Biorepository

C3 Steering Committee

Chair (rotating)

Scott M. Lippman (UCSD Moores) *

Co-Chairs

Tony Hunter (Salk)Garth Powis (Sanford-Burnham)

* All three Institutes are represented on the AACR Board of Directors in 2014

Members

Webster Cavenee (UCSD Moores)David Cheresh (UCSD Moores)Barbara Parker (UCSD Moores)

Ron Evans (Salk) *Inder Verma (Salk)Geoff Wahl   (Salk)

Sara Courtneidge  (Sanford-Burnham)Ze’ev Ronai (Sanford-Burnham)Kristiina Vuori (Sanford-Burnham) *

Ira Goodman (UCSD Moores)A.D. Admin

Participating SRs:• Negotiated an agreement to share unique resources at each institution that are

unavailable at the other 2 Cancer Centers (CC)

• All institutions agreed to give CC members, no matter the institution, the same priority and rates as internal CC users

• Institutions agreed to reduce the IDC charged to users from the other 2 CC  Moores: from 45% to 16% (SOM Dean agreed to waive 29% academic

portion)Salk: from 95% to 16%SBMRI: from 35% to 16%

• CC agreed to cover IDC (16%) using developmental funds from their respective CCSGs (not part of formal agreement)

• All institutions agreed that standard services provided by the shared resources would not involve intellectual property

• C3 agreement has increased usage of the three cores by users at the other CCs during the first year

C3 Resource Sharing

CANCER CENTERS COUNCIL

Sanford | Burnham Cancer Center – High Throughput Screening Core

Shared Resources Director Craig Hauser, PhD

Core Leader Michael Jackson, PhD

Core UsersMatthew Petroski, PhDJeffrey Smith, PhD Robert Wechsler-Reya, PhD

Salk Cancer Center – Gene Transfer Targeting and Therapeutics Core

Shared Resources DirectorJames Fitzpatrick, PhD

Core LeaderLeszek Lisowski, PhD

Core UsersJan Karlseder, PhDBen Spike, PhD  

UC San Diego Moores Cancer Center – Biorepository Core

Shared Resources DirectorNicholas Webster, PhD

Core LeaderScott VandenBerg, MD, PhD

Core UsersClark Chen, MD, PhDFrank Furnari, PhDMichael Karin, PhDAndrew Lowy, MD

C3 Scientific Retreat:June 29, 2013

Keynote Address 

Tony Hunter, PhD“Tyrosine Kinases in Cancer Biology and Treatment: Past, Present, Future”

Support for C3 Team Science

C3 Website & Pilot Grant RFA

www.sdcancercouncil.org

C3 Pilot Grant Applications

PI Title InstitutionsBall/Kang Predictive microenvironment for testing leukemia therapies Moores/SBMRI

Castro/Burkhart Targeting the Spliceosome in CLL Moores/Moores

Chen/SnyderHarnessing the anti-glioblastoma activity of extracellular vesicles (EV) derived from human neural stem cells (hNSCs)

Moores/SBMRI

Durden/Snyder Effects of dual PI-3K/Brd4 bromodomain inhibitors on NSCs and transformed NSCs Moores/SBMRI

Field/Jackson Small molecule screen for inhibitors of the GOLPH3 pathway Moores/SBMRI

Harismendy/Wechsler-Reya Mechanisms of resistance to HDAC inhibitors in medulloblastoma Moores/SBMRI

Husain/ShawOncogene addicted metabolic reprogramming of circulating tumor cells in lung adenocarcinoma

Moores/Salk

Karin/Wahl Applying p38 MAPK inhibitors to tackle breast cancer metastasis Moores/Salk

Li/Zhou Circulating microRNA in lung cancer early diagnosis Moores/SBMRI

Lowy/Wahl Stromal reprogramming to enhance the effectiveness of pancreatic cancer therapy Moores/Salk

Madlensky/Wahl Demonstrating the clinical utility of whole exome sequencing for cancer patients Moores/Salk

Niwa/Heynan-GenelDissecting two distinct IRE1 RNase activities as a new therapeutic strategy in multiple myeloma and other cancers

Moores/SBMRI

Puri/SchwabAbl-mediated tyrosine-phosphorylation of p300 acetyl-transferase as a biomarker for tumor chemo-resistance and dasatinib-sensitivity

Moores/SBMRI

Rana/Ramamoorthy Identification of non-coding RNA targets in oncogenic KRAS driven colon cancer SBMRI/Moores

Sicklick/Wechsler-Reya Targeting imatinib-resistant, KIT-negative cells in human GISTs Moores/SBMRI

Strongin/Bouvet PTK7 pseudokinase, a novel marker and a drug target in metastatic cancer SBMRI/Moores

Yu/Rana APOBEC deaminases in primary and metastatic melanoma Moores/SBMRI

Field/Jackson Small molecule screen for inhibitors of the GOLPH3 pathway Moores/SBMRI

Lowy/Wahl Stromal reprogramming to enhance the effectiveness of pancreatic cancer therapy Moores/Salk

new

Scott M. Lippman, MDDirector, Moores Cancer Center

Chugai Pharmaceutical Chair, Professor of MedicineAssociate Vice Chancellor for Cancer Research and Care

San Diego NCI Cancer Centers Council (C3):

A Model for Multi‐Institutional Transdisciplinary Collaboration